Lotus Pharmaceutical Co., Ltd. is a specialty pharmaceutical company focused on the development, manufacturing, licensing, and commercialization of generic and biosimilar drugs. The company operates a diversified portfolio of difficult-to-manufacture generics, with a primary focus on the oncology and immunology therapeutic areas. Key products include Lenalidomide, Suboxone, Nintedanib, and Vinorelbine soft capsules, with Semaglutide in the development pipeline. The company also holds rights to UroVaxom in South Korea and is advancing biosimilar candidates for Durvalumab and Emicizumab in partnership with Alvotech. Lotus Pharmaceutical serves markets in the United States, Japan, and major Asian regions. Its subsidiary Norwich is involved in the development of Rifaximin. The company utilizes a composite product strategy that combines in-house research and development with business development partnerships to expand access to critical therapies.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Drug Manufacturers - Specialty & Generic Homepage lotuspharm.com.tw
Sector Healthcare IR page lotuspharm.com.tw/zh-TW/investors
Tags
specialty generics, biosimilars, oncology, immunology, difficult generics, pharmaceutical manufacturing, drug development, licensing partnerships, Lenalidomide, Suboxone, Nintedanib, Vinorelbine, Semaglutide, UroVaxom, Diazoxide Choline, Rifaximin, Durvalumab, Emicizumab, Pomalidomide, Norwich, Alvotech
Press page lotuspharm.com.tw/zh-TW/newsroom

Metrics

Valuation  
Market cap NT$ 29.705B
Market cap (USD) $ 901.598M
P/E 13.12
PEG 0.82
P/BV 1.20
P/S 0.96
P/OCF 4.83
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 21.0%
ROI 19.8%
ROIC 20.5%
Profit margin 23.0%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 16.0%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 3
Quality score 37.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Revenue 20.509B 18.584B 16.958B 14.633B 12.649B 10.729B 9.175B 6.429B 6.424B 5.903B 5.522B 2.31B 658.481M 503.153M 532.209M 590.184M
Net profit 4.72B 5.066B 4.106B 3.021B 1.403B 1.027B 662.807M 99.476M 21.791M -134.041M 103.949M -442.127M 11.882M -193.234M -38.403M 15.051M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Share price 283 269.5 272 246 97.5 80 — — — — — — — — — —
Price performance 12m 0.05 -0.01 0.11 1.52 0.22 — — — — — — — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Lotus Pharmaceutical Co., Ltd. (ticker 1795.TW), listed in Taiwan.

ETFs Holding Lotus Pharmaceutical Co., Ltd.

ETF Weight in ETF Shares Market value As of
AVEE 0.04% 13,195 $ 50.794K Nov 16, 2026
DFAE 0.00% 64,832 $ 306.762K Nov 12, 2026
DFAX 0.00% 54,209 $ 256.498K Nov 12, 2026
DFEV 0.00% 4,364 $ 20.649K Nov 12, 2026
AVEM 0.00% 216,628 $ 833.914K Nov 16, 2026
AVES 0.00% 14,884 $ 57.296K Nov 16, 2026
AVXC 0.00% 1,286 $ 4,950.48 Nov 16, 2026